[The effect of dilazep on circulating platelet aggregation in diabetics].
The aim of the present paper was to evaluate the effect of the 1,4 bis [3-(3,4,5-trimethoxybenzoyl-oxy) propyl] perhydro-1,4 diazepina (dilazep) on reduction of circulating platelet aggregates in 18 patients with type 2 diabetes, 13 female and 5 male, aged 25-65 years. Dilazep was orally given at 100 mg X 3/day for 8 weeks. The platelet activity has valued before and after the treatment trough the evaluation of circulating platelet aggregates with the method of Wu and Hoak. The results confirmed that the dilazep decreased statistically significant after 8 weeks the circulating aggregates.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001381:Azepines / Q000494:pharmacology*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D004109:Dilazep / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*
D001381:Azepines; D004109:Dilazep
Studio dell'azione del dilazep sugli aggregati piastrinici circolanti in diabetici.